G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/53 (2006.01) A61K 31/353 (2006.01) A61K 45/00 (2006.01) A61P 9/00 (2006.01) A61P 9/10 (2006.01) A61P 25/00 (2006.01) A61P 25/28 (2006.01) A61P 35/00 (2006.01) A61P 37/08 (2006.01) G01N 33/15 (2006.01) G01N 33/50 (2006.01)
Patent
CA 2523186
It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiareteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiareteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby.
L'invention concerne une nouvelle méthode de criblage d'un médicament au moyen de l'utilisation d'un récepteur de laminine 67 kDa et un médicament ainsi obtenu. La méthode de criblage d'un médicament possède un effet d'inhibition de la prolifération cellulaire, un effet inhibiteur de l'angiogenèse, un effet d'inhibition de métastase cellulaire cancéreuse, un effet de protection nerveuse, un effet antiallergique, un effet antiartériosclérotique et/ou un effet d'inhibition d'une infection par la maladie de Creutzfeldt-Jakob. Ladite méthode consiste à mesurer qualitativement ou quantitativement le degré de liaison d'un composé d'essai à un récepteur de laminine 67 kDa, et évaluer que le composé d'essai est un médicament possédant un effet d'inhibition de la prolifération cellulaire, un effet d'inhibition de l'angiogenèse, un effet d'inhibition de métastase cellulaire cancéreuse, un effet de protection nerveuse, un effet antiallergique, un effet antiartériosclérotique et/ou un effet d'inhibition d'une infection par la maladie de Creutzfeldt-Jakob, au cas où les résultats de la mesure montrent que le composé d'essai se lie au récepteur de laminine 67 kDa. Cette invention a aussi trait à un médicament ainsi obtenu.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Kyushu Tlo Company Limited
LandOfFree
Method of screening drug with the use of 67 kda laminin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of screening drug with the use of 67 kda laminin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of screening drug with the use of 67 kda laminin... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1849763